<DOC>
	<DOCNO>NCT03007030</DOCNO>
	<brief_summary>The goal clinical research study learn Adcetris ( brentuximab vedotin ) help control mesothelioma . The safety drug also study .</brief_summary>
	<brief_title>Trial Adcetris CD30+ Malignant Mesothelioma</brief_title>
	<detailed_description>Study Drug Administration : There 21 day ( 3 week ) study cycle . If find eligible take part study , receive brentuximab vedotin vein 30 minute Day 1 every cycle . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete follow-up ( describe ) . Study Visits : On Day 1 every cycle : - You physical exam - Blood ( 4 teaspoon ) draw routine test Every 6 week study , PET-CT scan check status disease . Follow-Up : The study doctor study team follow 30 day last dose brentuximab vedotin either review medical record call learn side effect . You continue follow-ups 3 month , 6 month , every 6 month study . This investigational study . Brentuximab vedotin FDA approve commercially available treatment Hodgkin lymphoma anaplastic large cell lymphoma . It consider investigational use brentuximab vedotin patient mesothelioma . The study doctor explain study drug design work . Up 50 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 2 . Female subject either : a. postmenopausal least one year screen visit ; b. surgically sterilize ; c. willing use acceptable method birth control ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study least 6 month last dose brentuximab vedotin . 3 . Male subject , even surgically sterilize ( ie , status postvasectomy ) , agree use acceptable barrier method contraception ( condom spermicidal agent ) , completely abstain heterosexual intercourse entire study treatment period 6 month last dose brentuximab vedotin . 4 . Absolute neutrophil count ( ANC ) &gt; 1500/mm³ , platelet &gt; 100,000/mm³ , Hgb &gt; 8.5 g/dL . 5 . Total bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) , serum glutamate oxaloacetate transaminase ( SGOT ) ( AST ) serum glutamate pyruvate transaminase ( SGPT ) ( ALT ) &lt; 3 x ULN . AST and/or ALT may 5X ULN know liver mets 6 . Adequate renal function define : Calculated creatinine clearance must &gt; /= 30 mL/minute 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 8 . Pathologic diagnosis malignant mesothelioma ( primary site acceptable , histology acceptable ) 9 . Have unresectable malignant mesothelioma ( histology ) 10 . Positive CD30+ immunohistochemical expression 11 . Any line prior therapy patient may chemonaïve chemorefractory ( line ) 12 . Patients must measurable disease modify RECIST RECIST . Examinations assessment measurable disease must complete within 28 day prior registration . 13 . Patient must &gt; /= 18 year age 1 . Radiation therapy 25 % bone marrow . Whole pelvic radiation consider 25 % . 2 . Prior allogeneic bone marrow organ transplantation 3 . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum Betahuman chorionic gonadotropin ( BhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . 4 . Patient receive investigational drug 14 day enrollment 5 . Serious medical psychiatric illness likely interfere participation clinical study . 6 . No prior history malignancy within 2 year , unless cure skin cancer stage IIII solid tumor . No prior hematologic malignancy within 3 year . 7 . Known hypersensitivity brentuximab vedotin component 8 . Persons incarcerate time enrollment ( e.g. , prisoner ) likely become incarcerated study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lung Diseases Due External Agents</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>Unresectable malignant pleural mesothelioma</keyword>
	<keyword>MPM</keyword>
	<keyword>CD30+</keyword>
	<keyword>Brentuximab vedotin</keyword>
	<keyword>SGN-35</keyword>
	<keyword>Adcetris</keyword>
</DOC>